The Lazzaro Spallanzani National Institute for Infectious Diseases is an infectious disease hospital in the Italian city of Rome. The institute is named for the eighteenth-century Italian biologist Lazzaro Spallanzani. It is the Italian national reference center for Ebola patients.

During the past decade, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S. conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 6 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S." #1 sponsor was "Gilead Sciences" with 7 trials, followed by "Abbott" with 1 trials sponsored, "Avexa" with 1 trials sponsored, "Casa Sollievo della Sofferenza IRCCS" with 1 trials sponsored and "Janssen Vaccines & Prevention B.V." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S." #1 collaborator was "Arcispedale S. Anna, Ferrara" with 1 trials as a collaborator, "Azienda Ospedaliera V. Cervello" with 1 trials as a collaborator, "Azienda Ospedaliera, Lucca" with 1 trials as a collaborator, "Azienda Ospedaliera, Siracusa" with 1 trials as a collaborator and "Azienda Ospedaliero Universitaria di Sassari" with 1 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S." are "HIV-1 Infection" (5 trials), "HIV Infections" (3 trials), "Acquired Immunodeficiency Syndrome" (1 trials), "Chronic Hepatitis" (1 trials) and "Healthy" (1 trials). Many other conditions were trialed in "Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S." in a lesser frequency.

Most popular intervention types in "Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S." are "Drug" (11 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "ABC/3TC" (2 trials), "B/F/TAF" (2 trials), "E/C/F/TAF" (2 trials), "FTC/TDF" (2 trials) and "3TC" (1 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S." are 12 trials for "All" genders.

Currently, there are NaN active trials in "Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".